Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II high-dose myeloablative therapy with peripheral blood stem cell support in elderly patients with relapsed or refractory aggressive non-Hodgkin lymphoma
2013-003256-20Phase 2Terminated
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, cytarabine, rituximab, carboplatin and etoposide in non-Hodgkin lymphoma (NHL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival. Started Sep 2013; status: terminated.
02
Drugs
cisplatincytarabinerituximabcarboplatinetoposide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2013-003256-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003256-20.